肽安全吗：临床研究证据全面解析
肽安全吗？本文基于临床研究证据，系统梳理肽类药物的安全性数据，涵盖NMPA批准的肽类药物不良反应率、国内外临床试验结果及中国研究者的最新发现，帮助您科学评估肽的安全性。
最新研究
肽安全吗：临床研究证据全面解析
肽安全吗？本文基于临床研究证据，系统梳理肽类药物的安全性数据，涵盖NMPA批准的肽类药物不良反应率、国内外临床试验结果及中国研究者的最新发现，帮助您科学评估肽的安全性。
FDA Approves Lilly's Foundayo — the First GLP-1 Pill You Can Take Any Time Without Food Restrictions
The FDA approved orforglipron (Foundayo), Eli Lilly's once-daily oral GLP-1 receptor agonist for obesity. Unlike Novo Nordisk's oral Wegovy, Foundayo has no food or water restrictions, marking a major convenience leap for the 100+ million Americans with obesity.
FDA Approves ICOTYDE — the First Oral Peptide That Targets IL-23 for Psoriasis
Johnson & Johnson's ICOTYDE (icotrokinra) is the first oral peptide to precisely block the IL-23 receptor, offering complete skin clearance in a once-daily pill for moderate-to-severe plaque psoriasis. Approved March 18, 2026, it could replace injections as first-line systemic therapy.
3rd Peptide-Based Therapeutics Summit Opens in Boston as Industry Hits Inflection Point
The 3rd Peptide-Based Therapeutics Summit convenes in Boston in April 2026, bringing together researchers, pharma executives, and regulators as the peptide drug market is projected to reach $54.6 billion. Key themes include oral delivery breakthroughs, AI-driven peptide design, and the FDA's shifting regulatory posture.
Unnatural Products Raises $45M to Build Oral Macrocyclic Peptides for 'Undruggable' Targets
Santa Cruz biotech Unnatural Products closed a $45M Series B led by The Venture Collective, following a potential $1.7B Novartis collaboration. The company engineers synthetic macrocyclic peptides that can be taken orally and hit targets that traditional small molecules and antibodies cannot reach.
Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review
A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, finding selective cytotoxicity against tumor cells via membrane disruption and apoptosis induction, though clinical evidence remains limited to early-phase trials.
Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial
The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing significant MASH resolution without worsening fibrosis at 24 weeks. FDA granted Breakthrough Therapy designation in January 2026.
Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial
Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight reduction at 68 weeks in the pivotal TRIUMPH-4 trial — the largest weight loss ever reported for any anti-obesity medication in Phase 3.
什么是肽？肽在体内如何发挥作用：完全指南
肽是由2-50个氨基酸通过肽键连接而成的短链分子，在人体中充当信号传递者、激素和神经递质。本文从分子结构、合成机制、生理功能到中国NMPA监管框架，全面解析肽的科学原理与应用前景，帮助您建立对肽类物质的系统认知。
Article
Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial
Today · 1 min read
Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial
Today · 1 min read
Liposomal Delivery Enhances Collagen Tripeptide Effects on Skin Structure
4 days ago · 1 min read
Determinants of VO2peak Responsiveness to Aerobic Exercise Training in Adults with Type 2 Diabetes: The PROTECTION Study
6 days ago · 1 min read
热门话题
掌握最新动态
临床更新、行业新闻、新研究摘要和工具发布通知。
我们尊重你的隐私。可随时取消订阅。